OTC: ESMC
ESCALON MEDICAL CORPCIK 0000862668 · SIC 3845 · Electromedical Equipment
Micro
Revenue $13M
Assets $5M
as of Oct 14, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (NRIX 10-Q) is open in full — no account needed.
10-K
Filed Oct 13, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
10-Q
Filed May 15, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
Partner
Trade ESMC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
10-Q
Filed Feb 17, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
8-K
Filed Jan 29, 2026
· Period ending Jan 23, 2026
Summary not yet generated.
10-Q
Filed Nov 14, 2025
· Period ending Sep 30, 2025
Summary not yet generated.
10-K
Filed Sep 29, 2025
· Period ending Jun 30, 2025
Summary not yet generated.
8-K
Filed Apr 4, 2025
· Period ending Apr 2, 2025
Summary not yet generated.
8-K
Filed Nov 2, 2022
· Period ending Oct 28, 2022
Summary not yet generated.
10-K/A
Filed Oct 22, 2021
· Period ending Jun 30, 2021
Summary not yet generated.
424B3
Filed Apr 21, 2004
Summary not yet generated.
10-Q/A
Filed Apr 11, 2003
· Period ending Dec 31, 2002
Summary not yet generated.
Latest financial statements
From 10-K filed Oct 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations
| Description | Years ended June 30, 2026 | Years ended June 30, 2025 |
|---|---|---|
| Net revenues: | ||
| Products | 12,082,609 | 11,514,336 |
| Service plans | 653,536 | 531,812 |
| Revenues, net | 12,736,145 | 12,046,148 |
| Costs and expenses: | ||
| Cost of revenue | 7,166,609 | 6,535,090 |
| Marketing, general and administrative | 5,022,813 | 4,624,711 |
| Research and development | 501,488 | 753,130 |
| Total costs and expenses | 12,690,910 | 11,912,931 |
| Income from operations | 45,235 | 133,217 |
| Other expense | ||
| Gain from sales of AXIS software | 2,813,525 | — |
| Other income (expense) | 21,876 | (5,000) |
| Interest expense, net | (7,459) | (22,692) |
| Total other income (expenses), net | 2,827,942 | (27,692) |
| Net income before income tax | 2,873,177 | 105,525 |
| Income tax benefit | 1,139,449 | — |
| Net income | 4,012,626 | 105,525 |
| Less undeclared dividends on preferred stocks | 51,600 | 51,528 |
| Less income allocated to convertible preferred stocks | 1,948,700 | 25,903 |
| Net income applicable to common stockholders | 2,012,326 | 28,094 |
| Net income per share | ||
| Basic income per share applicable to common stockholder | 0.27 | 0.00 |
| Diluted income per share | 0.27 | 0.00 |
| Weighted average shares—basic | 7,415,329 | 7,415,329 |
| Weighted average shares—diluted | 14,596,202 | 14,252,202 |
Consolidated Balance Sheets
| Description | June 30, 2026 | June 30, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | 3,065,468 | 545,835 |
| Restricted cash | — | 256,550 |
| Accounts receivable | 1,977,254 | 1,667,394 |
| Less: allowance for credit losses | (74,035) | (164,499) |
| Accounts receivable, net | 1,903,219 | 1,502,895 |
| Inventories | 1,733,984 | 2,142,263 |
| Other current assets | 309,255 | 164,394 |
| Total current assets | 7,011,926 | 4,611,937 |
| Property and equipment, net | 26,605 | 34,589 |
| Right-of-use assets | 827,057 | 253,953 |
| Licenses and patents, net | 8,134 | 29,792 |
| Net deferred tax assets | 1,139,449 | — |
| Other long term assets | 114,944 | 62,788 |
| Total assets | 9,128,115 | 4,993,059 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Current portion of note payable | — | 40,708 |
| Current portion of EIDL loan | 3,499 | 3,370 |
| Accounts payable | 928,562 | 1,387,192 |
| Accrued expenses | 817,529 | 633,422 |
| Related party accrued interest | — | 112,389 |
| Current portion of operating lease liabilities | 159,351 | 86,521 |
| Deferred revenue | 388,297 | 327,919 |
| Other short term liabilities | 91,254 | 93,727 |
| Total current liabilities | 2,388,492 | 2,685,248 |
| Note payable, net of current portion | — | 85,761 |
| Operating lease liabilities, net of current portion | 676,514 | 168,015 |
| EIDL loan, net of current portion | 135,376 | 138,928 |
| Total liabilities | 3,200,382 | 3,077,952 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $1,077,131 and $1,025,531) | 645,000 | 645,000 |
| Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding | 7,415 | 7,415 |
| Additional paid-in capital | 69,702,043 | 69,702,043 |
| Accumulated deficit | (64,426,725) | (68,439,351) |
| Total stockholders’ equity | 5,927,733 | 1,915,107 |
| Total liabilities and stockholders’ equity | 9,128,115 | 4,993,059 |
Consolidated Statements of Cash Flows
| Description | Years ended June 30, 2026 | Years ended June 30, 2025 |
|---|---|---|
| Cash Flows from Operating Activities: | ||
| Net income | 4,012,626 | 105,525 |
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: | ||
| Net gain from sales of AXIS software | (2,813,525) | — |
| Change in allowance for credit loss | (61,823) | (6,605) |
| Decrease in inventory valuation | — | (42,838) |
| Depreciation and amortization | 22,588 | 37,819 |
| Non cash lease expense | 114,137 | 211,191 |
| Deferred income tax | (1,139,449) | — |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (338,501) | 627,869 |
| Inventories | 408,279 | (486,307) |
| Other currents | (144,861) | 29,702 |
| Other long-term assets | (52,156) | — |
| Accounts payable | (458,630) | 29,970 |
| Accrued expenses | 209,107 | 45,105 |
| Related party accrued interest | (112,389) | — |
| Change in operating lease liability | (105,912) | (226,656) |
| Deferred revenue | 60,378 | 47,915 |
| Other short-term liabilities | (2,473) | 8,035 |
| Net cash (used in) provided by operating activities | (402,604) | 380,725 |
| Cash Flows from Investing Activities: | ||
| Purchase of equipment | (4,421) | (3,880) |
| Proceeds from sales of AXIS software | 2,975,000 | — |
| Consulting fee associated with sales of AXIS software | (175,000) | — |
| Net cash provided by (used in) investing activities | 2,795,579 | (3,880) |
| Cash Flows from Financing Activities: | ||
| Proceeds from related party loan | 100,000 | — |
| Repayment of EIDL loan | (3,423) | (3,382) |
| Repayment of note payable | (126,469) | (36,533) |
| Repayment of related party loan | (100,000) | — |
| Net cash used in financing activities | (129,892) | (39,915) |
| Net increase in cash, cash equivalents and restricted cash | 2,263,083 | 336,930 |
| Cash, and restricted cash, beginning of year | 802,385 | 465,455 |
| Cash, and restricted cash, end of year | 3,065,468 | 802,385 |
| Cash, and restricted cash consist of the following: | ||
| End of year | ||
| Cash | 3,065,468 | 545,835 |
| Restricted cash | — | 256,550 |
| 3,065,468 | 802,385 | |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗